While non-US companies expand their presence in the States, US biopharma companies are struggling to expand patient access globally. Janice MacLennan, Founder & CEO of Nmblr, writes that a shift in strategy is needed. US biopharma innovation is thriving. The market generated around $220 billion in revenue in 2024 and is forecast to reach $342 […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!